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CALCIUM ANTAGONISTS are a heterogenous group of compounds having different pharmacokinetic properties and pharmacodynamic effects.' For example, nifedipine produces greater peripheral vasodilatation than either verapamil or diltiazem, whereas verapamil is more potent than the other two drugs in reducing myocardial contractility. Verapamil and diltiazem decrease atrioventricular conduction, whereas therapeutic doses of nifedipine do not.2 '3 Several investigators have reported evidence of the existence of multiple binding sites for different subclasses of calcium antagonists. 4 5 Recently, diltiazem was shown to potentiate the pharmacologic effects of dihydropyridine calcium antagonists such as nitrendipine6`8 and nimodipine.9 Therefore, if one calcium antagonist fails to produce a satisfactory clinical response, it would seem reasonable to try another agent of this class, or a combination. In this study, we investigated the antianginal effect of diltiazem and nifedi-pine alone and in combination in patients with effort angina.
Subjects and methods
Study patients. The study group consisted of 11 patients (nine men and two women, average age 57 years, range 39 to 68) with stable effort angina. All of the patients had already performed at least two exercise tests before participation in this study. All patients showed reproducible positive results on the exercise test with regard to exercise-induced chest pain and ischemic electrocardiographic changes (horizontal or downsloping ST segment depression .0.1 mV for at least 0.08 sec after the J point). Selective coronary angiography demonstrated that every patient had significant coronary artery disease, defined as greater than 75% narrowing of the luminal diameter. Five patients had one-vessel, three patients had two-vessel, and three patients had three-vessel coronary artery disease. Two patients had a history of myocardial infarction, but were without episodes within the 6 months preceding the study.
Protocol. During the study period, all patients were admitted to the hospital and all antianginal medications other than sublingual isosorbide dinitrate (5 mg) were discontinued for at least 72 hr before the study. The study protocol consisted of four different treatment periods of 1 week each, and every patient underwent all four treatments in succession. Assignment to a specific sequence of treatments was random. The drugs and dosages were: placebo four times daily, 30 
Results
Exercise testing variables (table 1) Exercise tolerance time (figure 1). Compared with placebo, which resulted in a mean exercise tolerance time of 235.1 ± 52 sec, diltiazem prolonged exercise time to 342.3 + 101 sec (p < .01) and nifedipine prolonged it to 325.6 ± 73 sec (p < .01). The combination of both drugs further prolonged the mean exercise tolerance time to 451.1 ± 103 sec, which was significantly better than the results achieved with either diltiazem (p < .01) or nifedipine (p < .01) alone.
Time to onset of chest pain. The time to onset of chest pain was prolonged from 150.5 ± 61 sec in the placebo period to 221.3 + 69 sec (p < .01) with diltiazem and to 236.5 ± 74 sec (p < .01) with nifedipine. The combination therapy further prolonged time to onset of chest pain to 340.5 ± 104 sec, which again was significantly better than the results with either diltiazem (p < .01) or nifedipine (p < .01) monotherapy.
Time to 1 mm ST depression. The time to 1 mm ST depression was also prolonged by diltiazem (p < .05) and nifedipine (p < .05), but was more significantly prolonged by the combination treatment (p < .01).
Magnitude ofST depression at corresponding exercise level in the drug and placebo periods. The magnitude of ST depression with combination therapy was 0.78 ± 0.5 mm, which was significantly smaller than that measured after diltiazem (p < .05) or nifedipine (p < .05) monotherapy.
Plasma concentration (figure 2). The plasma concentration of diltiazem was 66.3 ± 28 ng/ml when it was administered alone and 66.2 ± 18 ng/ml when it was administered concomitantly with nifedipine; the difference was not significant. On the other hand, the plasma concentration of nifedipine increased in all patients when nifedipine was administered concomitantly with diltiazem from 34.8 ± 1 1 ng/ml during monotherapy to 106.4 ± 37 ng/ml during combination therapy (p < .001).
Hemodynamic effects (table 2) Rest. The resting heart rate was decreased slightly but not significantly by diltiazem and was increased (p < .05) by nifedipine. When diltiazem and nifedipine were given concomitantly, the resting heart rate showed no statistically significant change in comparison with nifedipine alone. Systolic blood pressure was lowered by both diltiazem (not significant) and nifedipine (p < .01), and was reduced even more (p < .05 relative to nifedipine monotherapy) when the two drugs were given concomitantly. The pressure-rate product did not change significantly during any treatment periods. Maximal exercise. The maximal heart rate increased slightly with drug therapy, together with a prolongation of exercise tolerance time from 107.8 ± 10/min during the placebo period to 113. diltiazem and 115.4 ± 13/min after nifedipine. Although neither of these increases was significant, the combined drug treatment did significantly increase the heart rate to 126.2 ± 15/min (p < .01 relative to placebo and diltiazem and nifedipine monotherapy).
The systolic blood pressure showed no statistically significant changes. The pressure-rate product increased slightly with each treatment and was highest during combination therapy, but these changes also were not statistically significant. drugs,'5-18 especially ,3-blockers. In our study, the concomitant administration of diltiazem and nifedipine was expected to neutralize certain problems that occur with their use individually, e.g., diltiazem suppresses the tachycardia caused by pronounced sympathetic activation with nifedipine. We postulated that this combination therapy would be beneficial, particularly in patients with disorders for which /3-blockers are considered to be contraindicated, such as vasospastic angina, diabetes mellitus, bronchial asthma, and arteriosclerosis obliterans.
Our results indicate that combination therapy with diltiazem and nifedipine significantly increases exercise tolerance in patients with effort angina. Moreover, the plasma concentration of nifedipine increases about threefold with concomitant administration of diltiazem. It is not clear whether the superiority of the combination treatment derived mainly from an additive effect of diltiazem or an augmentation of nifedipine's effect due to its increased plasma concentration. However, since the effects of nifedipine are known to be dose dependent,"4 9, 20 the elevated plasma concentration of the drug during combination therapy probably contributed importantly to the enhanced effectiveness. Farringer et al.29 reported that the plasma concentration of quinidine was lower when nifedipine was added than when quinidine was given alone and that this decrease was associated with a reduced pharmacodynamic effect. Interactions between theophylline and verapamil,' cyclosporin and diltiazem,31 and propranolol and diltiazem32 have also been reported. However, whether or not the altered drug metabolism that results from the addition of a calcium antagonist produces any appreciable clinical effects is unclear at present.
Mechanisms of the interaction of diltiazem and nifedipine. The mechanisms of drug interactions with calcium antagonists are not well understood, including those of the interaction between diltiazem and nifedipine seen in this study. Etoh et al.32 reported an increase in the plasma concentration of propranolol on its coadministration with diltiazem, and speculated that this interaction involved a diminished first-pass metabolic clearance of propranolol secondary to an increase in hepatic blood flow induced by diltiazem. However, this proposed mechanism does not explain the increased plasma level of nifedipine associated with concomitant administration of diltiazem. Such a mechanism would also raise the diltiazem plasma concentration, since nifedipine is a stronger vasodilator than diltiazem and diltiazem undergoes more extensive first-pass metabolism than does nifedipine (their bioavailabilities are 42%33 and 55% to 63%, 34 In summary, the results of this study indicate that, in patients with effort angina, exercise tolerance is increased by the concomitant administration of diltiazem and nifedipine. This effect appears to be partly a consequence of an increase in the nifedipine plasma concentration as an expression of drug interaction. We believe this to be the first report of a clinically useful interaction, specifically in terms of therapy for effort angina, between these two agents.
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